nurix logo
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Partners
  • Platform
    • DELigase
    • Targeted Protein Degradation
    • Targeted Protein Elevation
    • Drug-Enhanced Cell Therapy
  • Pipeline
    • Pipeline
    • BTK Degraders
    • Immuno-Oncology
    • Adoptive Cell Therapy
  • Scientific Resources
    • Posters & Presentations
    • Videos
    • Mechanisms of Action
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Information
    • Corporate Governance
    • FAQs
  • Careers & Culture
  • Job Openings
  • Contact
Presentations

Discovery and Optimization of CBL-B Inhibitors

Presentations

ASH Event Presentation

Presentations

Molecular Property Prediction Using Machine Learning

Presentations

Chemistry @Nurix: Protein Modulation for Drug Discovery

Presentations

The CBL-B Inhibitor, NX-0255, Improves Human Drug Enhanced Tumor Infiltrating Lymphocyte (DeTIL-0255) Expansion and T-cell Function in Full-scale Runs 

Presentations

Universal Expansion of CBL-B–inhibited Tumor-Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation 

Presentations

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies 

Presentations

Initial Clinical Characterization of Novel Proximal Biomarkers for NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies 

Presentations

A Novel Small Molecule Inhibitor of CBL-B Shows Potent Antitumor Activity in Combination with Pmel-1 Adoptive Cell Transfer in an Aggressive Mouse Melanoma Model 

Presentations

NX-1607, a Small Molecule Inhibitor of the CBL-B E3 Ubiquitin Ligase, Promotes T and NK Cell Activation and Enhances NK-mediated ADCC in a Mouse Lymphoma Tumor Model 

nurix logo

 ©2023 Nurix Therapeutics, Inc.

Explore

  • About
  • Platform
  • Pipeline
  • Scientific Resources
  • Investors
  • Careers & Culture
  • Job Openings
  • Contact

Contact

1700 Owens Street, Suite 205
San Francisco, CA 94158

Direct: 415-660-5320
Fax: 415-525-4200

info@nurix-inc.com

  

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
MENU logo'
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Partners
  • Platform
    • DELigase
    • Targeted Protein Degradation
    • Targeted Protein Elevation
    • Drug-Enhanced Cell Therapy
  • Pipeline
    • Pipeline
    • BTK Degraders
    • Immuno-Oncology
    • Adoptive Cell Therapy
  • Scientific Resources
    • Posters & Presentations
    • Videos
    • Mechanisms of Action
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Information
    • Corporate Governance
    • FAQs
  • Careers & Culture
  • Job Openings
  • Contact